Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease

American Journal of Cardiology

Volumn 108, Issue 10, 2011, Pages 1483-1488

  Monfredi, Oliver ^a   Griffiths, Linda ^b   Clarke, Bernard ^a,b   Mahadevan, Vaikom S ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; LIVER ENZYME; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; DOWN SYNDROME; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EISENMENGER COMPLEX; ENZYME BLOOD LEVEL; EXERCISE TOLERANCE; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEG EDEMA; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SEX DIFFERENCE; SIDE EFFECT; SKIN PRURITUS; SYMPTOMATOLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIHYPERTENSIVE AGENTS; ASPARTATE AMINOTRANSFERASES; DOWN SYNDROME; EXERCISE TOLERANCE; FEMALE; HEART DEFECTS, CONGENITAL; HEMOGLOBINS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OXYGEN; RETROSPECTIVE STUDIES; SEX FACTORS; SULFONAMIDES;

EID: 80255123462     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.07.006     Document Type: Article

References (19)

1. N. Gali, M. Beghetti, M.A. Gatzoulis, J. Granton, R.M. Berger, A. Lauer, E. Chiossi, M. Landzberg Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54 (Pubitemid 44305274)
2. N. Gali, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, L. Rubin, M. Zellweger, and G. Simonneau Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 2009 1219 1263
3. N. Gali, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau ESC Committee for Practice Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
4. I. Schulze-Neick, N. Gilbert, R. Ewert, C. Witt, E. Gruenig, B. Enke, M.M. Borst, P.E. Lange, and M.M. Hoeper Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy Am Heart J 150 2005 716
5. G.P. Diller, K. Dimopoulos, M.G. Kaya, C. Harries, A. Uebing, W. Li, E. Koltsida, J.S. Gibbs, and M.A. Gatzoulis Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart 93 2007 974 976 (Pubitemid 47122051)
6. S.C. Apostolopoulou, A. Manginas, D.V. Cokkinos, and S. Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart 93 2007 350 354 (Pubitemid 46579526)
7. R.L. van Loon, E.S. Hoendermis, M.G. Duffels, A. Vonk-Noordegraaf, B.J. Mulder, H.L. Hillege, and R.M. Berger Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 154 2007 776 782 (Pubitemid 47429578)
8. K. Durongpisitkul, D. Jakrapanichakul, and S. Sompradikul A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease J Med Assoc Thai 91 2008 196 202 (Pubitemid 351413679)
9. M.G. Duffels, J.C. Vis, R.L. van Loon, P.T. Nieuwkerk, A.P. van Dijk, E.S. Hoendermis, R.H. de Bruin-Bon, B.J. Bouma, P. Bresser, R.M. Berger, and B.J. Mulder Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome Am J Cardiol 103 2009 1309 1315
10. E. Kotlyar, R. Sy, A.M. Keogh, F. Kermeen, P.S. Macdonald, C.S. Hayward, K.D. McNeil, and D.S. Celermajer Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease Cardiol Young 16 2006 268 274 (Pubitemid 44269416)
11. O. Sitbon, M. Beghetti, J. Petit, L. Iserin, M. Humbert, V. Gressin, and G. Simonneau Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects Eur J Clin Invest 36 suppl 3 2006 25 31 (Pubitemid 44179778)
12. R. Ibrahim, J.T. Granton, and S. Mehta An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease Can Respir J 13 2006 415 420 (Pubitemid 46138705)
13. M. D'Alto, C.D. Vizza, E. Romeo, R. Badagliacca, G. Santoro, R. Poscia, B. Sarubbi, M. Mancone, P. Argiento, F. Ferrante, M.G. Russo, F. Fedele, and R. Calabr Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart 93 2007 621 625 (Pubitemid 46707118)
14. M.A. Gatzoulis, M. Beghetti, N. Gali, J. Granton, R.M. Berger, A. Lauer, E. Chiossi, M. Landzberg BREATHE-5 Investigators Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study Int J Cardiol 127 2008 27 32 (Pubitemid 351707527)
15. F.D. Kermeen, C. Franks, K. O'Brien, H. Seale, K. Hall, K. McNeil, and D. Radford Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21 Heart Lung Circ 19 2010 595 600
16. E.L. Tay, A. Peset, M. Papaphylactou, R. Inuzuka, R. Alonso-Gonzalez, G. Giannakoulas, A. Tzifa, S. Goletto, C. Broberg, K. Dimopoulos, and M.A. Gatzoulis Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome Int J Cardiol 149 2011 372 376
17. R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, V.F. Tapson, D.B. Badesch, S. Roux, M. Rainisio, F. Bodin, and L.J. Rubin Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123 (Pubitemid 32971843)
18. N. Gali, L.J. Rubin, M. Hoeper, P. Jansa, H. Al-Hiti, G. Meyer, E. Chiossi, A. Kusic-Pajic, and G. Simonneau Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100 (Pubitemid 351902178)
19. K. Dimopoulos, R. Inuzuka, S. Goletto, G. Giannakoulas, L. Swan, S.J. Wort, and M.A. Gatzoulis Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension Circulation 121 2010 20 25